Favipiravir for symptomatic COVID-19: A nationwide observational cohort study
Y Doi, T Ishihara, S Banno, M Ando, M Kondo - Journal of Infection and …, 2023 - Elsevier
Introduction Favipiravir, an antiviral agent with activity against SARS-CoV-2, was made
available to hospitals in Japan for off-label use among COVID-19 patients between 2020 …
available to hospitals in Japan for off-label use among COVID-19 patients between 2020 …
Favipiravir for symptomatic COVID-19: A nationwide observational cohort study
T Ishihara, S Banno, M Ando, M Kondo - Journal of Infection and …, 2022 - europepmc.org
Methods A nationwide observational cohort study was conducted on patients who received
favipiravir as part of clinical care between February 2020 and December 2021. Information …
favipiravir as part of clinical care between February 2020 and December 2021. Information …
Favipiravir for symptomatic COVID-19: A nationwide observational cohort study
Y Doi, T Ishihara, S Banno, M Ando… - Journal of Infection and …, 2023 - jiac-j.com
Introduction Favipiravir, an antiviral agent with activity against SARS-CoV-2, was made
available to hospitals in Japan for off-label use among COVID-19 patients between 2020 …
available to hospitals in Japan for off-label use among COVID-19 patients between 2020 …
Favipiravir for symptomatic COVID-19: A nationwide observational cohort study
Y Doi, T Ishihara, S Banno, M Ando… - Journal of infection …, 2023 - pubmed.ncbi.nlm.nih.gov
Introduction Favipiravir, an antiviral agent with activity against SARS-CoV-2, was made
available to hospitals in Japan for off-label use among COVID-19 patients between 2020 …
available to hospitals in Japan for off-label use among COVID-19 patients between 2020 …
[HTML][HTML] Favipiravir for symptomatic COVID-19: A nationwide observational cohort study
Y Doi, T Ishihara, S Banno, M Ando… - Journal of Infection and …, 2023 - ncbi.nlm.nih.gov
Methods A nationwide observational cohort study was conducted on patients who received
favipiravir as part of clinical care between February 2020 and December 2021. Information …
favipiravir as part of clinical care between February 2020 and December 2021. Information …
Favipiravir for symptomatic COVID-19: a nationwide observational cohort study.
Y Doi, T Ishihara, S Banno, M Ando, M Kondo - 2023 - cabidigitallibrary.org
Introduction: Favipiravir, an antiviral agent with activity against SARS-CoV-2, was made
available to hospitals in Japan for off-label use among COVID-19 patients between 2020 …
available to hospitals in Japan for off-label use among COVID-19 patients between 2020 …
[引用][C] JIC award 2023
Y Doi, T Ishihara, S Banno, M Ando, M Kondo - J Infect Chemother, 2023 - jiac-j.com
Introduction: Favipiravir, an antiviral agent with activity against SARS-CoV-2, was made
available to hospitals in Japan for off-label use among COVID-19 patients between 2020 …
available to hospitals in Japan for off-label use among COVID-19 patients between 2020 …
Favipiravir for symptomatic COVID-19: A nationwide observational cohort study.
T Ishihara, S Banno, M Ando, M Kondo - Journal of Infection and …, 2022 - europepmc.org
Methods A nationwide observational cohort study was conducted on patients who received
favipiravir as part of clinical care between February 2020 and December 2021. Information …
favipiravir as part of clinical care between February 2020 and December 2021. Information …